MMP inhibitors in cardiac diseases

An update

György Dormán, Katalin Kocsis-Szommer, Cesare Spadoni, P. Ferdinándy

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Close to 60 matrix metalloproteinase (MMP) inhibitors have been pursued as clinical candidates since the first drug discovery program targeting this enzyme family began in the late seventies. Targeted indications included cancer, arthritis, cardiovascular diseases, and many others. However, the clinical development of most of the MMP inhibitors have been discontinued due to safety reasons and so far only Periostat (doxycycline hyclate, a nonspecific MMP inhibitor) has been approved for periodontal disease. Because of the high therapeutic potential, the devriopment of MMP inhibitors continues as shown by several recent patents and scientific publications. Development of selective MMP inhibitors lacking serious side-effects such as musculoskeletal syndrome is of high importance. Innovative approaches for the design of selective MMP inhibitors include the integration of classical medicinal chemistry structure-based properties and design features into the emerging chemogenomics concept of target-family based drug discovery. This approach, which includes privileged structures, molecular frameworks, bioisosteric and bioanalogous/isofunctional modifications (the "matrixinome" approach), may lead to highly selective MMP inhibitors in the future.

Original languageEnglish
Pages (from-to)186-194
Number of pages9
JournalRecent Patents on Cardiovascular Drug Discovery
Volume2
Issue number3
DOIs
Publication statusPublished - Nov 2007

Fingerprint

Matrix Metalloproteinase Inhibitors
Heart Diseases
Doxycycline
Drug Discovery
Patents
Pharmaceutical Chemistry
Periodontal Diseases
Molecular Structure
Arthritis
Publications
Cardiovascular Diseases
Safety
Enzymes
Neoplasms

Keywords

  • Efficacy
  • Heart failure
  • Infarction
  • Inhibitors
  • Matrix metalloproteinase
  • MMP
  • Remodelling
  • Safety
  • Selectivity

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)
  • Drug Discovery

Cite this

MMP inhibitors in cardiac diseases : An update. / Dormán, György; Kocsis-Szommer, Katalin; Spadoni, Cesare; Ferdinándy, P.

In: Recent Patents on Cardiovascular Drug Discovery, Vol. 2, No. 3, 11.2007, p. 186-194.

Research output: Contribution to journalArticle

Dormán, György ; Kocsis-Szommer, Katalin ; Spadoni, Cesare ; Ferdinándy, P. / MMP inhibitors in cardiac diseases : An update. In: Recent Patents on Cardiovascular Drug Discovery. 2007 ; Vol. 2, No. 3. pp. 186-194.
@article{ce47ba0825ed4f6d919f9f209c18263b,
title = "MMP inhibitors in cardiac diseases: An update",
abstract = "Close to 60 matrix metalloproteinase (MMP) inhibitors have been pursued as clinical candidates since the first drug discovery program targeting this enzyme family began in the late seventies. Targeted indications included cancer, arthritis, cardiovascular diseases, and many others. However, the clinical development of most of the MMP inhibitors have been discontinued due to safety reasons and so far only Periostat (doxycycline hyclate, a nonspecific MMP inhibitor) has been approved for periodontal disease. Because of the high therapeutic potential, the devriopment of MMP inhibitors continues as shown by several recent patents and scientific publications. Development of selective MMP inhibitors lacking serious side-effects such as musculoskeletal syndrome is of high importance. Innovative approaches for the design of selective MMP inhibitors include the integration of classical medicinal chemistry structure-based properties and design features into the emerging chemogenomics concept of target-family based drug discovery. This approach, which includes privileged structures, molecular frameworks, bioisosteric and bioanalogous/isofunctional modifications (the {"}matrixinome{"} approach), may lead to highly selective MMP inhibitors in the future.",
keywords = "Efficacy, Heart failure, Infarction, Inhibitors, Matrix metalloproteinase, MMP, Remodelling, Safety, Selectivity",
author = "Gy{\"o}rgy Dorm{\'a}n and Katalin Kocsis-Szommer and Cesare Spadoni and P. Ferdin{\'a}ndy",
year = "2007",
month = "11",
doi = "10.2174/157489007782418964",
language = "English",
volume = "2",
pages = "186--194",
journal = "Recent Patents on Cardiovascular Drug Discovery",
issn = "1574-8901",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - MMP inhibitors in cardiac diseases

T2 - An update

AU - Dormán, György

AU - Kocsis-Szommer, Katalin

AU - Spadoni, Cesare

AU - Ferdinándy, P.

PY - 2007/11

Y1 - 2007/11

N2 - Close to 60 matrix metalloproteinase (MMP) inhibitors have been pursued as clinical candidates since the first drug discovery program targeting this enzyme family began in the late seventies. Targeted indications included cancer, arthritis, cardiovascular diseases, and many others. However, the clinical development of most of the MMP inhibitors have been discontinued due to safety reasons and so far only Periostat (doxycycline hyclate, a nonspecific MMP inhibitor) has been approved for periodontal disease. Because of the high therapeutic potential, the devriopment of MMP inhibitors continues as shown by several recent patents and scientific publications. Development of selective MMP inhibitors lacking serious side-effects such as musculoskeletal syndrome is of high importance. Innovative approaches for the design of selective MMP inhibitors include the integration of classical medicinal chemistry structure-based properties and design features into the emerging chemogenomics concept of target-family based drug discovery. This approach, which includes privileged structures, molecular frameworks, bioisosteric and bioanalogous/isofunctional modifications (the "matrixinome" approach), may lead to highly selective MMP inhibitors in the future.

AB - Close to 60 matrix metalloproteinase (MMP) inhibitors have been pursued as clinical candidates since the first drug discovery program targeting this enzyme family began in the late seventies. Targeted indications included cancer, arthritis, cardiovascular diseases, and many others. However, the clinical development of most of the MMP inhibitors have been discontinued due to safety reasons and so far only Periostat (doxycycline hyclate, a nonspecific MMP inhibitor) has been approved for periodontal disease. Because of the high therapeutic potential, the devriopment of MMP inhibitors continues as shown by several recent patents and scientific publications. Development of selective MMP inhibitors lacking serious side-effects such as musculoskeletal syndrome is of high importance. Innovative approaches for the design of selective MMP inhibitors include the integration of classical medicinal chemistry structure-based properties and design features into the emerging chemogenomics concept of target-family based drug discovery. This approach, which includes privileged structures, molecular frameworks, bioisosteric and bioanalogous/isofunctional modifications (the "matrixinome" approach), may lead to highly selective MMP inhibitors in the future.

KW - Efficacy

KW - Heart failure

KW - Infarction

KW - Inhibitors

KW - Matrix metalloproteinase

KW - MMP

KW - Remodelling

KW - Safety

KW - Selectivity

UR - http://www.scopus.com/inward/record.url?scp=36749017556&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36749017556&partnerID=8YFLogxK

U2 - 10.2174/157489007782418964

DO - 10.2174/157489007782418964

M3 - Article

VL - 2

SP - 186

EP - 194

JO - Recent Patents on Cardiovascular Drug Discovery

JF - Recent Patents on Cardiovascular Drug Discovery

SN - 1574-8901

IS - 3

ER -